Lytix Biopharma AS reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was NOK 1.41 million. Revenue was NOK 2.97 million compared to NOK 1.91 million a year ago. Net loss was NOK 11.15 million compared to NOK 18.91 million a year ago.
For the nine months, sales was NOK 1.41 million compared to NOK 0.017 million a year ago. Revenue was NOK 15.66 million compared to NOK 25.11 million a year ago. Net loss was NOK 26.81 million compared to NOK 31.65 million a year ago.